{
    "organizations": [],
    "uuid": "9ff76179ec196422fdf1762bd5669f3534b312e0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-stada-says-ema-starts-evaluation-o/brief-stada-says-ema-starts-evaluation-of-resubmitted-pegfilgrastim-application-idUSASM000K03",
    "ord_in_thread": 0,
    "title": "BRIEF-Stada Says EMA Starts Evaluation Of Resubmitted Pegfilgrastim Application",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 2 (Reuters) - Stada:\n* DGAP-NEWS: STADA ARZNEIMITTEL AG: EMA STARTED THE EVALUATION OF RESUBMITTED MARKETING AUTHORISATION APPLICATION FOR BIOSIMILAR PEGFILGRASTIM\n* ‍EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED REGULATORY RESUBMISSION OF ITS PROPOSED BIOSIMILAR TO AMGEN’S NEULASTA​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-02T16:38:00.000+02:00",
    "crawled": "2018-03-03T17:31:56.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "stada",
        "stada",
        "arzneimittel",
        "ag",
        "ema",
        "started",
        "evaluation",
        "resubmitted",
        "marketing",
        "authorisation",
        "application",
        "biosimilar",
        "pegfilgrastim",
        "medicine",
        "agency",
        "ema",
        "accepted",
        "regulatory",
        "resubmission",
        "proposed",
        "biosimilar",
        "amgen",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}